...KRAS (n = 16). The NLP pipeline achieved high accuracy in extracting clinical concepts, with an F1-score of 79.7% for tu...
...KRAS pathway was enriched in stromal cells only. Profiling KRAS and downstream signaling in lungs from individuals with ...
...KRASG12C and KRASG12D mutations (ASPC-1, PANC-1 and Miapac-2) and excellent selectivity between cancerous and non-cancer...
...KRAS mutant cells. Despite over 90% of pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations, PDAC exh...
...KRAS by adapting error-corrected Maximum Depth Sequencing (K-MDS) for whole blood. K-MDS detected oncogenic KRAS mutatio...
...KRAS, while founding lesions such as DNMT3A were usually retained. Clonal evolution patterns varied, with constant profi...
...KRAS G12C inhibitors. Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis. There were no significant d...
...KRAS effectors and phosphoinositide 3-kinase-AKT. By integrating mechanistic insights with therapeutic perspectives, we ...
...KRAS mutation (12%) compared with those without EGFR/KRAS mutations (2%, P < .001 and P = .07, respectively). In tumors ...
...KRAS mutations, leading to the disruption of cell cycle regulation. Utilizing molecular docking, we identified 3-aminois...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
